Summarized by Masters of Longevity from PR Newswire.
Company reported >$1 billion product sales and multiple clinical program starts.
Key Takeaways
- Net product sales were reported above $1 billion this quarter.
- Phase 1 trials for two obesity candidates were initiated and ongoing.
- Phase 3 programs for osavampator and direclidine are advancing.
